Could Novo, Lilly become first trillion-dollar healthcare companies?

By every measure, weight loss drugs have quickly and dramatically transformed Novo Nordisk.

Fueled by the massive uptake of its GLP-1 agonists Ozempic and Wegovy in the last few years, Novo overtook luxury retailer LVMH as the most valuable company in Europe in September — a position maintained with a market cap of more than $500 billion, which is greater than the GDP of Novo’s home country, Denmark.